Product image of Myocet Liposomal (Doxorubicin Hydrochloride) supplied by GNH India

Myocet Liposomal

Active Ingredient:
Doxorubicin Hydrochloride
Origin:
EU

Myocet Liposomal (Doxorubicin Hydrochloride)

Doxorubicin Hydrochloride, the active ingredient in Myocet Liposomal, is an anthracycline antibiotic presented as a liposomal injection for intravenous use. The liposomal formulation enhances tumor targeting and reduces cardiac exposure, and it is indicated for the treatment of metastatic breast cancer and ovarian cancer in adult patients.

GNH India supplies Myocet Liposomal as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, ensuring quality‑controlled sourcing from the European market. The company provides full regulatory documentation and cold‑chain logistics where required.

Manufacturer / TM Owner

Cheplapharm Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myocet Liposomal (doxorubicin hydrochloride) is used in oncologic therapy targeting rapidly dividing tumor cells.

  • Metastatic breast cancer: improves response rates and disease control in patients with advanced disease.
  • Ovarian cancer: provides therapeutic benefit in recurrent or refractory ovarian carcinoma.
  • Recurrent ovarian cancer: used as a treatment option when standard chemotherapy has failed.

How It Works

  • Doxorubicin hydrochloride intercalates between DNA base pairs and inhibits topoisomerase II, preventing DNA replication and transcription. The liposomal carrier delivers the drug preferentially to tumor tissue, enhancing intracellular concentration while limiting exposure to healthy cardiac cells. Additionally, the drug generates free radicals that cause oxidative damage to cancer cell membranes, leading to apoptosis.

Side Effects

Myocet Liposomal may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea and vomiting: gastrointestinal upset commonly reported during treatment.
  • Alopecia: reversible hair loss affecting scalp and body hair.
  • Fatigue: generalized tiredness that may affect daily activities.
  • Neutropenia: reduced neutrophil count increasing infection risk.
  • Anemia: lowered red blood cell levels causing weakness.
  • Mucositis: inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects

  • Cardiotoxicity: potential for reduced left ventricular function or heart failure.
  • Severe myelosuppression: profound decrease in all blood cell lines.
  • Febrile neutropenia: fever associated with low neutrophil count.
  • Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
  • Secondary leukemia: rare development of therapy‑related leukemia.
  • Pulmonary toxicity: interstitial pneumonitis or fibrosis.

Precautions & Warnings

When using Myocet Liposomal, clinicians should observe several safety measures.

  • Cardiac monitoring: assess baseline left ventricular function and repeat assessments during therapy.
  • Dose adjustments: modify dosing in patients with hepatic impairment or reduced organ function.
  • Avoid concurrent cardiotoxic agents: limit exposure to other drugs that may increase cardiac risk.
  • Monitor blood counts: perform regular CBCs to detect myelosuppression early.
  • Pregnancy and lactation: use only if potential benefits outweigh risks to mother and fetus.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Myocet Liposomal can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Concurrent anthracyclines: additive cardiotoxicity may occur.
  • Live vaccines: immunosuppression increases infection risk.
  • Chest radiation therapy: combined treatment heightens cardiac toxicity.

Moderate Interactions (Monitor Closely)

  • Azole antifungals: may raise plasma levels of doxorubicin.
  • Strong CYP450 inhibitors: potential alteration of drug metabolism.
  • St. John’s wort: herbal induction may reduce therapeutic efficacy.

Frequently Asked Questions

Myocet Liposomal contains doxorubicin hydrochloride in a liposomal formulation and is used as an intravenous antineoplastic agent for the treatment of metastatic breast cancer and ovarian cancer in adult patients.

The drug intercalates into DNA and blocks topoisomerase II, causing DNA strand breaks. The liposomal carrier concentrates the agent in tumor tissue and generates free radicals that trigger cancer cell death while limiting exposure to healthy heart tissue.

The specific dose and schedule are determined by the prescribing oncologist based on the patient’s condition, body surface area, and treatment protocol. Dosing is individualized and should follow the approved label or clinical guidelines.

Safety in pregnancy and lactation has not been established. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant, and alternative therapies should be considered whenever possible.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Myocet Liposomal uses a liposomal delivery system that improves tumor targeting and reduces cardiac exposure compared with conventional doxorubicin formulations. This may result in a more favorable safety profile, especially regarding cardiotoxicity, while maintaining antitumor efficacy.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging to maintain stability until it is prepared for administration.

Myocet Liposomal is given as an intravenous infusion by a qualified healthcare professional. The infusion rate and duration are set by the treating physician according to the prescribed dose and patient tolerance.

The most serious risks include cardiotoxicity leading to heart failure, severe myelosuppression (especially neutropenia and febrile neutropenia), secondary leukemia, and hypersensitivity reactions that can be life‑threatening. Patients should be monitored closely for these events.

Patients with pre‑existing severe cardiac disease, uncontrolled infections, known hypersensitivity to doxorubicin or liposomal components, and those receiving other cardiotoxic agents without appropriate monitoring should generally avoid Myocet Liposomal. Final eligibility is determined by the prescribing clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Doxorubicin Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT